Wockhardt Limited (WOCKPHARMA) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹2,032 (+1.28% day change)
Key ratios
- P/E ratio
- 154.88
- P/B ratio
- 3.86
- ROE (%)
- 4.31
- ROCE (%)
- 5.76
- Debt/Equity
- 0.45
- Dividend yield (%)
- 0
- Market cap (₹ Cr)
- 33,017.16
Forensic checks
Piotroski F-Score: 7/9 · Altman Z-Score: 6.04 · Beneish M-Score: -2.69
InvestSights quality score
57.3/100 — Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q4 FY26)
AI summary: Wockhardt's Q4 FY26 earnings call marked a pivotal moment, with the launch of Zaynich—a novel antibiotic targeting carbapenem-resistant infections—set to redefine its growth trajectory. Management emphasized Zaynich's differentiation, robust clinical data, and strategic market entry in the US, India, and emerging markets. While initial commercialization challenges and upfront…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.